openPR Logo
Press release

ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

05-05-2025 11:34 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies 2025:

DelveInsight's, "ER positive, HER2 negative Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive ER+/ HER2 -ve Breast Cancer Pipeline Report to explore emerging therapies, key ER+/ HER2 -ve Breast Cancer Companies, and future ER+/ HER2 -ve Breast Cancer treatment landscapes @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the ER+/ HER2 -ve Breast Cancer Pipeline Report

* In May 2025, InventisBio Co. Ltd announced Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
* DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment.
* The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others.
* Promising ER+/ HER2 -ve Breast Cancer Therapies such as Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others.

Discover how the ER+/ HER2 -ve Breast Cancer treatment paradigm is evolving. Access DelveInsight's in-depth ER+/ HER2 -ve Breast Cancer Pipeline Analysis for a closer look at promising breakthroughs @ ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ER+/ HER2 -ve Breast Cancer Emerging Drugs Profile

* Camizestrant: AstraZeneca

Camizestrant, is a next-generation oral selective estrogen receptor degrader (SERD), as a promising treatment for ER-positive, HER2-negative breast cancer. This drug, developed by AstraZeneca, and has shown significant potential in improving progression-free survival (PFS) compared to the standard treatment with fulvestrant, which has been the mainstay therapy for almost two decades. Camizestrant has demonstrated significant efficacy in clinical trials, particularly the SERENA-2 phase II trial. In this study, camizestrant was compared to fulvestrant, a well-established treatment. Patients receiving camizestrant showed improved progression-free survival (PFS) at doses of 75 mg and 150 mg, with median PFS of 7.2 and 9.2 months, respectively, compared to 3.7 months for those on fulvestrant. This trial also highlighted camizestrant's ability to reduce ESR1-mutant circulating tumor DNA, indicating a strong efficacy in combatting endocrine-resistant tumors. Safety profiles from these studies indicate that camizestrant is generally well-tolerated, with manageable side effects such as fatigue, anemia, and mild visual disturbances. The favorable balance between efficacy and safety has supported the advancement of camizestrant into further phase III trials, like SERENA-4 and SERENA-6, which are exploring its use in combination with CDK4/6 inhibitors for broader clinical application. Currently, the drug is in Phase III stage of its development for the treatment of HER2-negative breast cancer.

* (Z)-endoxifen: Atossa Therapeutics, Inc.

(Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKC1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase I studies and in a small Phase II study of women with breast cancer. Currently, the drug is in Phase II stage of its development for the treatment of ER-positive, HER2-negative breast cancer.

* AC699: Accutar Biotechnology Inc

AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) , and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ER degradation as demonstrated in preclinical studies. AC699 is currently being evaluated in an ongoing Phase I clinical study as a single agent for the treatment of ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary objectives are to evaluate the safety and tolerability of AC699. Secondary and exploratory objectives include pharmacokinetics, preliminary efficacy and pharmacodynamic evaluation. The study uses a 3+3 dose-escalation design, with once-daily oral dosing of AC699 at 100, 200, 300, 400, and 600 mg.

The ER+/ HER2 -ve Breast Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer Treatment.
* ER+/ HER2 -ve Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market.

Get a detailed analysis of the latest innovations in the ER+/ HER2 -ve Breast Cancer pipeline. Explore DelveInsight's expert-driven report today! @ ER+/ HER2 -ve Breast Cancer Unmet Needs [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ER+/ HER2 -ve Breast Cancer Companies

AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others.

ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming ER+/ HER2 -ve Breast Cancer Therapies and key ER+/ HER2 -ve Breast Cancer Developments @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report

* Coverage- Global
* ER+/ HER2 -ve Breast Cancer Companies- AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others.
* ER+/ HER2 -ve Breast Cancer Therapies- Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others.
* ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in ER+/ HER2 -ve Breast Cancer drug development? Find out in DelveInsight's exclusive ER+/ HER2 -ve Breast Cancer Pipeline Report-access it now! @ ER+/ HER2 -ve Breast Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* ER+/ HER2-VE Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* ER positive, HER2 negative Breast Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Camizestrant: AstraZeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* (Z)-endoxifen: Atossa Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AC699: Accutar Biotechnology Inc
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* ER+/ HER2-VE Breast Cancer Key Companies
* ER+/ HER2-VE Breast Cancer Key Products
* ER+/ HER2-VE Breast Cancer- Unmet Needs
* ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
* ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
* ER+/ HER2-VE Breast Cancer Analyst Views
* ER+/ HER2-VE Breast Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=er-her2-ve-breast-cancer-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here

News-ID: 4000135 • Views:

More Releases from ABNewswire

Modified Cassava Starch Market Size, Share, Growth Drivers, Emerging Trends, Opportunities, Top Companies, Recent Developments, and Forecast - 2030
Modified Cassava Starch Market Size, Share, Growth Drivers, Emerging Trends, Opp …
Modified Cassava Starch Market by Product Type (Pre-Gelatinized Starches, Extruded Cassava Starch, Dextrinized Starches, Maltodextrins, Fermented Cassava Starch), Form, Application, Type of Modification, Function, and Region - Global Forecast to 2030 The modified cassava starch market [https://www.marketsandmarkets.com/Market-Reports/modified-cassava-starch-market-104540605.html?utm_source=prnewswire.com&utm_medium=paid+pr&utm_campaign=modified-cassava-starch-market] is projected to grow from USD 2.52 billion in 2025 to USD 3.37 billion by 2030, at a CAGR of 6.0% from 2025 to 2030. As eating habits shift across regions, processed and packaged
Plywood Market Booming Worldwide Demand, Growth and Future Scope 2025-2030 | Expert Review
Plywood Market Booming Worldwide Demand, Growth and Future Scope 2025-2030 | Exp …
The plywood market continues to grow steadily, driven by rising demand in construction, furniture, and packaging sectors. Key players such as Boise Cascade Company, UPM-Kymmene Oyj, Georgia-Pacific LLC, Greenply Industries, and Century Plyboards focus on product quality, sustainability, and global expansion, shaping the competitive landscape and future market trends. The plywood market is expected to grow from USD 47.39 billion in 2024 to USD 60.31 billion by 2030, at a CAGR
Industrial Rubber Market Emerging Trends, Applications, and Growth Forecast by 2030
Industrial Rubber Market Emerging Trends, Applications, and Growth Forecast by 2 …
The Industrial Rubber Market is poised for steady growth, driven by rising demand from automotive, construction, and manufacturing sectors. Key players like Exxon Mobil, Dynasol Group, Synthos, ARLANXEO, and SIBUR are focusing on innovation and capacity expansion to meet evolving industry needs and global sustainability goals, strengthening their competitive edge. The global industrial rubber market is projected to grow from USD 11.48 billion in 2025 to USD 14.90 billion by 2030,
Geothermal Energy Market Size Expected to Reach $13.56 billion by 2030
Geothermal Energy Market Size Expected to Reach $13.56 billion by 2030
The global Geothermal Energy Market size is projected to grow from estimated USD 9.81 billion in 2024 to USD 13.56 billion by 2030, at a CAGR of 5.3% during the forecast period. The global [https://www.marketsandmarkets.com/Market-Reports/geothermal-energy-market-205152720.html#utm_source=abnewswire.com&utm_medium=Referral&utm_campaign=PaidPR] is projected to grow from estimated USD 9.81 billion in 2024 to USD 13.56 billion by 2030, at a CAGR of 5.3% during the forecast period. Increasing use of geothermal energy for power generation, favourable government

All 5 Releases


More Releases for HER2

Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period? Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period. Global HER2 Inhibitors Market Scope and Market Size The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain. Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report: • DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with